Prognostic value of serum amyloid A in COVID-19: A meta-analysis.
Medicine (Baltimore)
; 101(7): e28880, 2022 Feb 18.
Article
in English
| MEDLINE | ID: covidwho-1774439
ABSTRACT
BACKGROUND:
There is still a lack of large-scale clinical studies and evidence-based evidence to prove the relationship between serum amyloid A (SAA) and the severity and prognosis of patients with new coronavirus pneumonia (COVID-19).METHODS:
We searched PubMed, Cochrane Library, Excerpta Medica Database, and Web of Science for original articles from December 1, 2019 to December 19, 2020. Search criteria include free text search, explosive MESH/EMTREE terms, and all synonyms for SAA and COVID-19. There are no language restrictions on the searched documents. Statistical methods were performed using Stata 14.0 software, and RevMan 5.4 software provided by the Cochrane Collaboration for meta-analysis. The 10 included studies in the literature were classified according to the severity of the novel coronavirus treatment guidelines, with mild/moderate categorized as nonsevere and severe/critical as severe, and the data were meta-analyzed using multiple subgroup standard deviations combined. Severe and nonsevere were finally divided into 2 groups, and the combined data were meta-analyzed according to the standardized mean difference.RESULTS:
The results of the meta-analysis given by random effects showed that SAA levels were significantly higher in severe vs nonsevere (standardized mean difference 1.20 [95% confidence interval 0.91-1.48]), which was statistically significant (Pâ<â.001). The 3 literatures studied (random effect size 0.11 [95% confidence interval 0.05-0.19]; I2â=â56.68%) and were statistically significant, zâ=â5.46 Pâ<â.01, suggesting that the risk of death occurs at higher levels with increasing SAA values, with the risk of death in the severe group being 11% higher than in the nonsevere group.CONCLUSION:
SAA can be considered as a biomarker for predicting the severity and prognosis of COVID-19. SAA can be used for early warning of the poor prognosis of COVID-19 and for monitoring the recovery process, which has important clinical value.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Serum Amyloid A Protein
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Medicine (Baltimore)
Year:
2022
Document Type:
Article
Affiliation country:
Md.0000000000028880
Similar
MEDLINE
...
LILACS
LIS